Jorma J. Isola

Lääketieteellisen Teknologian Instituutti PL 607
Tampere, 33101, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 152 publications

Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates.

Drug-tolerant persisting polyploid giant cancer cells mediate resistance to HER2-targeting antibody-drug conjugates.

Journal: Cancer letters

Published: April 28, 2025

Clinicopathological comparison of eccrine poroma and porocarcinoma: Ki-67 index is not a decisive factor.

Clinicopathological comparison of eccrine poroma and porocarcinoma: Ki-67 index is not a decisive factor.

Journal: PloS one

Published: October 21, 2024

Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan.

Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan.

Journal: Translational oncology

Published: September 20, 2024

Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.

Safety, clinical activity, pharmacodynamics, and pharmacokinetics of IMU-856, a SIRT6 modulator, in coeliac disease: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.

Journal: The lancet. Gastroenterology & hepatology

Published: April 08, 2024

Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease.

Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease.

Journal: Nature immunology

Published: June 22, 2023

The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment.

The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment.

Journal: International journal of molecular sciences

Published: May 16, 2023

Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.

Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study.

Journal: The lancet. Gastroenterology & hepatology

Published: April 27, 2022

Healthy and pro-inflammatory gut ecology plays a crucial role in the digestion and tolerance of a novel Gluten Friendly™ bread in celiac subjects: a randomized, double blind, placebo control in vivo study.

Healthy and pro-inflammatory gut ecology plays a crucial role in the digestion and tolerance of a novel Gluten Friendly™ bread in celiac subjects: a randomized, double blind, placebo control in vivo study.

Journal: Food & function

Published: January 14, 2022

UV-induced local immunosuppression in the tumour microenvironment of eccrine porocarcinoma and poroma.

UV-induced local immunosuppression in the tumour microenvironment of eccrine porocarcinoma and poroma.

Journal: Scientific reports

Published: October 17, 2021

MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1/OCT4 levels.

MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1/OCT4 levels.

Journal: iScience

Published: October 04, 2021

A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.

A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease.

Journal: The New England journal of medicine

Published: June 30, 2021

Apolipoprotein A4 Defines the Villus-Crypt Border in Duodenal Specimens for Celiac Disease Morphometry.

Apolipoprotein A4 Defines the Villus-Crypt Border in Duodenal Specimens for Celiac Disease Morphometry.

Journal: Frontiers in immunology

Published: May 24, 2021

Showing 1-12 of 152

Last Updated: 09/26/2026